Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeloda Added to Herceptin and Taxotere in HER2+ Metastatic Breast Cancer
NCT02748213Phase 2Completed
- Sponsor
- Roche
- Start
- Feb 2002
- Primary completion
- Mar 2006
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 15
01
Overview
A Phase 2 trial of capecitabine in breast cancer, sponsored by Roche. Started Feb 2002; status: completed.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02748213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02748213.